Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432405 · ClinicalTrials.gov registry record · Phase 4
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
A Phase 4 study of Type 2 Diabetes Mellitus, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01432405: Completed Phase 4 study of Type 2 Diabetes Mellitus, sponsored by Baylor College of Medicine.
NCT01432405 is a Phase 4 study of Type 2 Diabetes Mellitus that has completed, run by Baylor College of Medicine. The registered enrollment target is 24 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01432405, a Phase 4 study of Type 2 Diabetes Mellitus, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effect of exenatide, an anti-diabetes medication, on liver fat and blood levels of proteins that influence liver fat.
Primary Outcome
The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Pioglitazone
- DRUG Exenatide
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
What the finished NCT01432405 record still lists
NCT01432405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Pioglitazone is the first listed.
NCT01432405 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01432405 about?
NCT01432405 is a clinical study titled "Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes". The purpose of this study is to examine the effect of exenatide, an anti-diabetes medication, on liver fat and blood levels of proteins that influence liver fat.
What is the current status of trial NCT01432405?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2007-06. Estimated completion is 2009-06.
What conditions does trial NCT01432405 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT01432405?
The interventions under investigation include: Pioglitazone (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT01432405?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01432405 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01432405's enrollment target sits among peer trials
24 101st of 130 higher than 24 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
ACTIVE NOT RECRUITING · Phase 4
-
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
COMPLETED · Phase 4
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
COMPLETED · Phase 4
-
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
COMPLETED · Phase 4
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia